

Injectable Fillers & Bulking Agents, Medical 153

Table of Content

[Description & Definitions](#)
[Criteria](#)
[Document History](#)
[Coding](#)
[Policy Approach and Special Notes](#)
[References](#)
[Keywords](#)

Effective Date	1/1/2026
Next Review Date	9/2026
Coverage Policy	Medical 153
Version	8

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual *.

Description & Definitions:

Bulking agents are substances in the form of a gel-like product used to fill in gaps, add volume or mass.

Injectable fillers (also known as Dermal or Soft Tissue Fillers) are injections of a substance into various parts of the body to smooth skin and wrinkles in addition to treatment of other medical conditions.

Types of Bulking Agents & Injectable Fillers:

- Autologous fat (Fat harvested from the patient's body)
- Calcium hydroxylapatite (naturally occurring mineral found in bones and teeth - e.g., Radiesse Voice, Prolarynx and Prolarynx Plus (formerly the Radiesse Laryngeal Implant))
- Collagen (protein found in connective tissue)
- Cymetra (micronized AlloDerm, tissue processed human tissue)
- Hyaluronic acid (naturally occurring substance in the body that attracts and holds water, e.g. Restylane, Juvederm, Revanesse)

Other names: injection medialization, Glottic Insufficiency, Vocal fold medialization

Criteria:

Bulking Agents & Injectable Fillers (a product prescribed is used according to U.S. Food and Drug Administration (FDA) labeled indications, contraindications, warnings, and precautions) are considered medically necessary with the treatment of **1 or more** of the following:

- Bulking Agents is considered medically necessary for the treatment of **1 or more** of the following medical conditions:
 - Glottis insufficiency resulting from **1 or more** of the following :
 - Abductor muscle spasmodic dysphonia
 - Parkinson's disease
 - Presbylaryngis
 - Unilateral vocal cord paralysis
 - Vocal fold atrophy
 - Vocal fold bowing

- Vocal fold scar
 - Vocal fold sulcus vocalis
- Velopharyngeal/velopalatal; insufficiency;
- Vocal cord insufficiency
- Injectable Fillers is considered medically necessary for the treatment of **All** of the following:
 - Individual has a diagnosis of human immunodeficiency virus (HIV)
 - Individual has facial lipodystrophy caused by antiretroviral medications which contributes significantly to depression
 - Individual is over the age of 21
 - The dermal filler to be used is approved by the Food and Drug Administration

Bulking Agents & Injectable Fillers are considered **not medically necessary** for any use other than those indicated in clinical criteria, to include but not limited to:

- Cosmetic indications
- Belotero Balance
- Captique
- Eleveess
- Esthéelis
- Hylaform
- Juvederm Ultra 2, 3 or 4
- Kybella
- Perlane
- Prevelle
- Puragen
- Revanesse Versa
- Stylage

Document History:

Revised Dates:

- 2025: September – Implementation date of January 1, 2026. Housekeeping, new formatting
- 2024: September – added criteria for dermal fillers and appropriate coding.
- 2022: September
- 2021: December
- 2019: November
- 2016: March
- 2014: February, July
- 2013: July
- 2011: September

Reviewed Dates:

- 2023: September
- 2020: December
- 2019: December
- 2018: June
- 2016: July
- 2015: July
- 2012: August

Origination Date: January 2011

Coding:

Medically necessary with criteria:

Coding	Description

31513	Laryngoscopy, indirect; with vocal cord injection
31570	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic
31571	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope
31574	Laryngoscopy, flexible; with injection(s) for augmentation (eg, percutaneous, transoral), unilateral
C1878	Material for vocal cord medialization, synthetic (implantable) [e.g., RenuVoice, RenuGel]
G0429	Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS) (e.g., as a result of highly active antiretroviral therapy)
L8607	Injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies
L8699	Prosthetic implant, not otherwise specified [when specified as a hyaluronic acid gel agent such as Juvederm or Restylane]
Q2026	Injection, Radiesse, 0.1 ml
Q2028	Injection, Sculptra, 0.5 mg
Q4112	Cymetra, injectable, 1 cc

Considered Not Medically Necessary:

Coding	Description
NONE	Mics (Injection of drug/substance under skin or into muscle)

The preceding codes are included above for informational purposes only and may not be all inclusive. Additionally, inclusion or exclusion of a treatment, procedure, or device-code(s) does not constitute or imply member coverage or provider reimbursement.

Policy Approach and Special Notes: *

- Coverage
 - See the appropriate benefit document for specific coverage determination. Member specific benefits take precedence over medical policy.
- Application to products
 - Policy is applicable to Sentara Health Plan Virginia Medicaid Products
- Authorization requirements
 - Precertification required by Plan
- Special Notes:
 - This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.
 - Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

- The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to “correct or ameliorate” (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member’s condition. [EPSDT Supplement B \(updated 5.19.22\) Final.pdf](#)
- Service authorization requests must be accompanied by sufficient clinical records to support the request. Clinical records must be signed and dated by the requesting provider within 60 days of the date of service requested.

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2025). Retrieved 6 2025, from MCG: <https://careweb.careguidelines.com/ed29/index.html>

(2025). Retrieved 7 2025, from Hayes:

<https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Bulking%2520Agents%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%2522%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sources%2522>

Clinical Practice Guideline: Hoarseness (Dysphonia) (2018 Update). (2018). Retrieved 8 2025, from American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS): <https://aao-hnsjournals.onlinelibrary.wiley.com/doi/10.1177/0194599817751030>

Current status and perspectives in the treatment of facial lipoatrophy in HIV-positive patients in 2024. (2024, 10). Retrieved 8 2025, from ScienceDirect: <https://pdf.sciencedirectassets.com/272225/1-s2.0-S0294126025X00030/1-s2.0-S029412602400178X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEEEaCXVzLWVhc3QtMSJIMEYCIQCF5p0fDJJe%2FGA3Si7I%2BbzhG2%2BuVPcwqJScyYxvTR4fwlhAKag7ZC%2BzMuZB8GXufPpYPkhwG%2FzbEcCqS>

Injectable soft tissue fillers: Overview of clinical use. (2025, 4). Retrieved 8 2025, from UpToDate: https://www.uptodate.com/contents/injectable-soft-tissue-fillers-overview-of-clinical-use?search=facial%20lipoatrophy&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#H1194119

Injection Augmentation. (2019). Retrieved 8 2025, from American Laryngological Association (ALA): https://alahns.org/wp-content/uploads/CLC/57_CLC_Injection-Augmentation.pdf

NCD DERMAL Injections for the Treatment of Facial Lipodystrophy Syndrome (LDS) 250.5. (2010). Retrieved 7 2025, from CMS: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncid=338&ncdver=1&bc=0>

Provider Manual. (2025). Retrieved 8 2025, from DMAS: <https://www.dmas.virginia.gov/for-providers/>

Velopharyngeal Insufficiency. (2023, 1). Retrieved 8 2025, from National Library of Medicine, StatPearls: <https://www.ncbi.nlm.nih.gov/books/NBK563149/>

Keywords:

SHP Bulking Agents for Vocal Cord Insufficiency, Radiess voice gel injection, shp medical 153, vocal cord, Glottis insufficiency, vocal cord fold, vocal fold injection, VFI, VFI bulking agents, Injection laryngoplasty, Voice Injectable Implant, vocal cord augmentation, Injection Augmentation